WO1995021919A2 - Proteine a activite de thrombopoietine (tpo) - Google Patents

Proteine a activite de thrombopoietine (tpo) Download PDF

Info

Publication number
WO1995021919A2
WO1995021919A2 PCT/JP1995/000208 JP9500208W WO9521919A2 WO 1995021919 A2 WO1995021919 A2 WO 1995021919A2 JP 9500208 W JP9500208 W JP 9500208W WO 9521919 A2 WO9521919 A2 WO 9521919A2
Authority
WO
WIPO (PCT)
Prior art keywords
tpo
polypeptide
dna
protein
cells
Prior art date
Application number
PCT/JP1995/000208
Other languages
English (en)
Other versions
WO1995021919A3 (fr
Inventor
Hiroshi Miyazaki
Takashi Kato
Kinya Ohgami
Akihiro Iwamatsu
Hiromichi Akahori
Ryota Kuroki
Toshiyuki Shimizu
Takanori Muto
Original Assignee
Kirin Brewery Company, Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to KR1019970702401A priority Critical patent/KR100260272B1/ko
Priority to PL95311885A priority patent/PL179884B1/pl
Priority to KR1019970702400A priority patent/KR100272867B1/ko
Priority to JP7521122A priority patent/JP2996729B2/ja
Application filed by Kirin Brewery Company, Limited filed Critical Kirin Brewery Company, Limited
Priority to BR9505781A priority patent/BR9505781A/pt
Priority to AU16718/95A priority patent/AU702669B2/en
Priority to EP95908381A priority patent/EP0695355A1/fr
Priority to NZ279555A priority patent/NZ279555A/en
Priority to RO95-01791A priority patent/RO118299B1/ro
Priority to MX9504057A priority patent/MX9504057A/es
Priority to KR1019950704474A priority patent/KR100237582B1/ko
Publication of WO1995021919A2 publication Critical patent/WO1995021919A2/fr
Priority to NO19954058A priority patent/NO323195B1/no
Priority to FI954889A priority patent/FI954889A/fi
Publication of WO1995021919A3 publication Critical patent/WO1995021919A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/524—Thrombopoietin, i.e. C-MPL ligand
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La présente invention porte sur des polypeptides de TPO ayant une activité biologique spécifique de stimulation ou d'accroissement de la production de plaquettes contenant la séquence d'aminoacides 1-332 de NO ID SEQ: 6 ou un dérivé, sur des molécules d'ADN codant des polypeptides de TPO, sur les procédés de production de ces polypeptides, sur des anticorps spécifiquement immunoréactifs vis-à-vis de ces polypeptides, sur des compositions pharmaceutiques contenant ces polypeptides, et sur les applications de ces polypeptides dans le traitement d'anomalies plaquettaires comme la thrombopénie.
PCT/JP1995/000208 1994-02-14 1995-02-14 Proteine a activite de thrombopoietine (tpo) WO1995021919A2 (fr)

Priority Applications (13)

Application Number Priority Date Filing Date Title
AU16718/95A AU702669B2 (en) 1994-02-14 1995-02-14 Protein having TPO activity
KR1019970702400A KR100272867B1 (ko) 1994-02-14 1995-02-14 Tpo활성을 갖는 단백질
JP7521122A JP2996729B2 (ja) 1994-02-14 1995-02-14 Ｔｐｏ活性タンパク質に対する抗体
NZ279555A NZ279555A (en) 1994-02-14 1995-02-14 Thrombopoietin polypeptides their production and use
BR9505781A BR9505781A (pt) 1994-02-14 1995-02-14 Proteina tendo atividade TPO
PL95311885A PL179884B1 (en) 1994-02-14 1995-02-14 Protein of tpo activity
EP95908381A EP0695355A1 (fr) 1994-02-14 1995-02-14 Proteine a activite de thrombopoietine (tpo)
KR1019970702401A KR100260272B1 (ko) 1994-02-14 1995-02-14 Tpo활성을 갖는 단백질의 아미노산을 코딩하는 염기 서열을 포함하는 dna
RO95-01791A RO118299B1 (ro) 1994-02-14 1995-02-14 Polipeptida trombopoietina, secventa adn care o codifica, procedeu pentru prepararea polipeptidei trombopoietine si compozitie farmaceutica cu aceasta
MX9504057A MX9504057A (es) 1994-02-14 1995-02-14 Proteina que tiene actividad tpo.
KR1019950704474A KR100237582B1 (ko) 1994-02-14 1995-02-14 Tpo 활성을 갖는 단백질의 제조방법
NO19954058A NO323195B1 (no) 1994-02-14 1995-10-12 Protein som har TPO aktivitet, DNA kodende for nevnte protein, fremstillingsmetoder, vertceller, farmasoytiske sammensetinger, anvendelser og antistoff
FI954889A FI954889A (fi) 1994-02-14 1995-10-13 Proteiini, jolla on TPO-aktiviteetti

Applications Claiming Priority (25)

Application Number Priority Date Filing Date Title
JP3909094 1994-02-14
JP6/39090 1994-02-14
US21216494A 1994-03-14 1994-03-14
JP7984294 1994-03-25
JP6/79842 1994-03-25
US22102094A 1994-04-01 1994-04-01
JP15512694 1994-06-01
JP6/155126 1994-06-01
JP6/167328 1994-06-15
JP16732894 1994-06-15
US27808394A 1994-07-20 1994-07-20
JP6/193169 1994-08-17
JP19316994 1994-08-17
JP6/227159 1994-08-17
JP22715994 1994-08-17
JP6/193916 1994-08-18
JP19391694 1994-08-18
US32030094A 1994-10-11 1994-10-11
JP6/304167 1994-11-01
JP30416794 1994-11-01
JP6/298669 1994-12-01
JP29866994 1994-12-01
US36181194A 1994-12-22 1994-12-22
JP6/341200 1994-12-28
JP34120094 1994-12-28

Publications (2)

Publication Number Publication Date
WO1995021919A2 true WO1995021919A2 (fr) 1995-08-17
WO1995021919A3 WO1995021919A3 (fr) 1995-12-07

Family

ID=27585306

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP1995/000208 WO1995021919A2 (fr) 1994-02-14 1995-02-14 Proteine a activite de thrombopoietine (tpo)

Country Status (1)

Country Link
WO (1) WO1995021919A2 (fr)

Cited By (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996028182A1 (fr) * 1995-03-15 1996-09-19 Kirin Brewery Company, Limited Procede pour empecher l'adsorption de tpo et composition stable contenant du tpo
WO1996028181A1 (fr) * 1995-03-15 1996-09-19 Kirin Brewery Company, Limited Procede pour empecher l'adsorption de tpo et composition contenant de la tpo
WO1996041642A1 (fr) * 1995-06-08 1996-12-27 Kirin Brewery Company, Limited Composition lyophilisee stable contenant de la thrombopoietine (tpo)
US5696250A (en) * 1995-02-15 1997-12-09 Amgen Inc. DNA encoding megakaryocyte growth and development factor analogs
US5766581A (en) * 1994-03-31 1998-06-16 Amgen Inc. Method for treating mammals with monopegylated proteins that stimulates megakaryocyte growth and differentiation
US5795569A (en) * 1994-03-31 1998-08-18 Amgen Inc. Mono-pegylated proteins that stimulate megakaryocyte growth and differentiation
EP0885242A1 (fr) * 1995-06-07 1998-12-23 Glaxo Group Limited Peptides et composes se fixant a un recepteur de thrombopoietine
US5869451A (en) * 1995-06-07 1999-02-09 Glaxo Group Limited Peptides and compounds that bind to a receptor
US5989538A (en) * 1995-02-15 1999-11-23 Amgen Inc. Mpl ligand analogs
US6251864B1 (en) 1995-06-07 2001-06-26 Glaxo Group Limited Peptides and compounds that bind to a receptor
WO2003086444A1 (fr) 2002-04-04 2003-10-23 Amgen Inc. Utilisation de fusions de transthyretine peptide/proteine destinees a accroitre la demi-vie serique de peptides/proteines actifs au plan pharmacologique
US6835809B1 (en) 1998-10-23 2004-12-28 Amgen Inc. Thrombopoietic compounds
WO2005033135A1 (fr) 2003-10-09 2005-04-14 Daewoong Co., Ltd. Procede de purification de la thrombopoietine humaine a teneur en acide sialique elevee
EP0804480B1 (fr) * 1994-12-30 2006-03-08 ZymoGenetics, Inc. Thrombopoietine purifiee et son procede d'obtention
US7091311B2 (en) 1996-06-07 2006-08-15 Smithkline Beecham Corporation Peptides and compounds that bind to a receptor
US7189827B2 (en) 1998-10-23 2007-03-13 Amgen Inc. Modified peptides as therapeutic agents
US7332474B2 (en) 2001-10-11 2008-02-19 Amgen Inc. Peptides and related compounds having thrombopoietic activity
US7576056B2 (en) 2003-08-28 2009-08-18 Ortho-Mcneil Pharmaceutical, Inc. Peptides and compounds that bind to a receptor
US7723295B2 (en) 2003-08-28 2010-05-25 Ortho-Mcneil Pharmaceutical, Inc. Peptides and compounds that bind to a receptor
EP2233150A2 (fr) 2003-12-30 2010-09-29 Augustinus Bader Erythropoietin pour utilisation dans la guérison de blessures ou la transplantation de cellules
US7981425B2 (en) 2006-06-19 2011-07-19 Amgen Inc. Thrombopoietic compounds
US8067367B2 (en) 2002-09-18 2011-11-29 Janssen Pharmaceutica, N.V. Methods of increasing platelet and hematopoietic stem cell production
EP2425860A1 (fr) 2005-08-12 2012-03-07 Amgen Inc. Molécules Fc modifiées
US8143380B2 (en) 2004-07-08 2012-03-27 Amgen Inc. Therapeutic peptides
US8147844B1 (en) 1994-01-03 2012-04-03 Genentech, Inc. Mpl ligand (thrombopoietin), nucleic acids encoding such, and methods of treatment using mpl ligand
US8178107B1 (en) 1994-01-03 2012-05-15 Genentech, Inc. Method of treatment of thrombocytopenia or risk thereof using MPL ligand (thrombopoietin), variants, and fragments thereof
US20120142595A1 (en) * 2005-08-05 2012-06-07 Araim Pharmaceuticals, Inc. Tissue protective peptides and uses thereof
US8241900B1 (en) 1994-01-03 2012-08-14 Genentech, Inc. mpl ligand
US8278099B1 (en) 1994-02-15 2012-10-02 Genentech, Inc. Monoclonal antibody to human thrombopoietin
US8399250B1 (en) 1994-01-03 2013-03-19 Genentech, Inc. Anti-mpl ligand (thromobpoietin) antibodies
US8420779B2 (en) 2007-05-22 2013-04-16 Amgen Inc. Compositions and methods for producing bioactive fusion proteins
US8853358B2 (en) 2008-01-22 2014-10-07 Araim Pharmaceuticals, Inc. Tissue protective peptides and peptide analogs for preventing and treating diseases and disorders associated with tissue damage
US9012605B2 (en) 2006-01-23 2015-04-21 Amgen Inc. Crystalline polypeptides

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
CELL, vol. 77, 1 July 1994 pages 1117-1124, BARTLEY ET AL 'IDENTIFICATION AND CLONING OF A MEGAKARYOCYTE GROWTH AND DEVLOPMENT FACTOR THAT IS A LIGAND FOR THE CYTOKINE RECEPTOR MPL' cited in the application *
EXPERIMENTAL HEMATOLOGY, vol. 16, no. 3, March 1988 pages 201-205, MCDONALD 'THROMBOPOIETIN:ITS BIOLOGY,PURIFICATION,AND CHARACTERIZATION' *
FEBS LETTERS, vol. 353, no. 1, 10 October 1994 pages 57-61, SOHMA ET AL 'MOLECULAR CLONING AND CHROMOSOMAL LOCALIZATION OF THE HUMAN THROMBOPOIETIN GENE' *
NATURE, vol. 369, 16 June 1994 pages 533-538, DE SAUVAGE ET AL 'STIMULATION OF MEGAKARYOCYTOPOIESIS AND THROMBOPOIESIS BY THE C-MPL LIGAND' cited in the application *

Cited By (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8178107B1 (en) 1994-01-03 2012-05-15 Genentech, Inc. Method of treatment of thrombocytopenia or risk thereof using MPL ligand (thrombopoietin), variants, and fragments thereof
US8192955B1 (en) 1994-01-03 2012-06-05 Genentech, Inc. Nucleic acids encoding MPL ligand (thrombopoietin), variants, and fragments thereof
US8399250B1 (en) 1994-01-03 2013-03-19 Genentech, Inc. Anti-mpl ligand (thromobpoietin) antibodies
US8147844B1 (en) 1994-01-03 2012-04-03 Genentech, Inc. Mpl ligand (thrombopoietin), nucleic acids encoding such, and methods of treatment using mpl ligand
US8241900B1 (en) 1994-01-03 2012-08-14 Genentech, Inc. mpl ligand
US8193323B1 (en) 1994-01-03 2012-06-05 Genentech, Inc. mpl ligand (thrombopoietin), active fragments thereof, and fusion proteins and compositions comprising mpl ligand and other cytokines
US8278099B1 (en) 1994-02-15 2012-10-02 Genentech, Inc. Monoclonal antibody to human thrombopoietin
US5795569A (en) * 1994-03-31 1998-08-18 Amgen Inc. Mono-pegylated proteins that stimulate megakaryocyte growth and differentiation
US5766581A (en) * 1994-03-31 1998-06-16 Amgen Inc. Method for treating mammals with monopegylated proteins that stimulates megakaryocyte growth and differentiation
EP0804480B1 (fr) * 1994-12-30 2006-03-08 ZymoGenetics, Inc. Thrombopoietine purifiee et son procede d'obtention
US5756083A (en) * 1995-02-15 1998-05-26 Amgen Inc. Mpl ligand analogs
US5989538A (en) * 1995-02-15 1999-11-23 Amgen Inc. Mpl ligand analogs
US5696250A (en) * 1995-02-15 1997-12-09 Amgen Inc. DNA encoding megakaryocyte growth and development factor analogs
US7399833B1 (en) 1995-02-15 2008-07-15 Elliott Steven G MGDF analogs
WO1996028181A1 (fr) * 1995-03-15 1996-09-19 Kirin Brewery Company, Limited Procede pour empecher l'adsorption de tpo et composition contenant de la tpo
WO1996028182A1 (fr) * 1995-03-15 1996-09-19 Kirin Brewery Company, Limited Procede pour empecher l'adsorption de tpo et composition stable contenant du tpo
US6465430B1 (en) 1995-06-07 2002-10-15 Smithkline Beecham Corporation Peptides and compounds that bind to a thrombopoietin receptor
EP0885242A1 (fr) * 1995-06-07 1998-12-23 Glaxo Group Limited Peptides et composes se fixant a un recepteur de thrombopoietine
US6251864B1 (en) 1995-06-07 2001-06-26 Glaxo Group Limited Peptides and compounds that bind to a receptor
US6121238A (en) * 1995-06-07 2000-09-19 Glaxo Wellcome Inc. Peptides and compounds that bind to a receptor
EP0885242A4 (fr) * 1995-06-07 2000-03-22 Glaxo Group Ltd Peptides et composes se fixant a un recepteur de thrombopoietine
US6506362B1 (en) 1995-06-07 2003-01-14 Glaxo Group Limited Labeled compounds that bind to a thrombopoietin receptor
US5869451A (en) * 1995-06-07 1999-02-09 Glaxo Group Limited Peptides and compounds that bind to a receptor
WO1996041642A1 (fr) * 1995-06-08 1996-12-27 Kirin Brewery Company, Limited Composition lyophilisee stable contenant de la thrombopoietine (tpo)
US8227422B2 (en) 1996-06-07 2012-07-24 Glaxosmithkline Llc Peptides and compounds that bind to a receptor
US7091311B2 (en) 1996-06-07 2006-08-15 Smithkline Beecham Corporation Peptides and compounds that bind to a receptor
US9534032B2 (en) 1998-10-23 2017-01-03 Amgen Inc. Thrombopoietic compounds
EP2319928A1 (fr) 1998-10-23 2011-05-11 Kirin-Amgen, Inc. Thrombopoietines dimériques et mimétiques se liant au récepteur MP1 et ayant une activité thrombopoietique
US7189827B2 (en) 1998-10-23 2007-03-13 Amgen Inc. Modified peptides as therapeutic agents
US6835809B1 (en) 1998-10-23 2004-12-28 Amgen Inc. Thrombopoietic compounds
US7332474B2 (en) 2001-10-11 2008-02-19 Amgen Inc. Peptides and related compounds having thrombopoietic activity
EP2298331A2 (fr) 2002-04-04 2011-03-23 Amgen, Inc Utilisation de fusions de peptides/protéines de transthyrétine pour augmenter la demi-vie sérique de peptides/protéines pharmacologiquement actifs
WO2003086444A1 (fr) 2002-04-04 2003-10-23 Amgen Inc. Utilisation de fusions de transthyretine peptide/proteine destinees a accroitre la demi-vie serique de peptides/proteines actifs au plan pharmacologique
US8067367B2 (en) 2002-09-18 2011-11-29 Janssen Pharmaceutica, N.V. Methods of increasing platelet and hematopoietic stem cell production
US8283313B2 (en) 2002-09-18 2012-10-09 Janssen Pharmaceutica, Nv Methods of increasing platelet and hematopoietic stem cell production
US7723295B2 (en) 2003-08-28 2010-05-25 Ortho-Mcneil Pharmaceutical, Inc. Peptides and compounds that bind to a receptor
US7576056B2 (en) 2003-08-28 2009-08-18 Ortho-Mcneil Pharmaceutical, Inc. Peptides and compounds that bind to a receptor
WO2005033135A1 (fr) 2003-10-09 2005-04-14 Daewoong Co., Ltd. Procede de purification de la thrombopoietine humaine a teneur en acide sialique elevee
EP2233150A2 (fr) 2003-12-30 2010-09-29 Augustinus Bader Erythropoietin pour utilisation dans la guérison de blessures ou la transplantation de cellules
US8143380B2 (en) 2004-07-08 2012-03-27 Amgen Inc. Therapeutic peptides
US20120142595A1 (en) * 2005-08-05 2012-06-07 Araim Pharmaceuticals, Inc. Tissue protective peptides and uses thereof
US10100096B2 (en) 2005-08-05 2018-10-16 Araim Pharmaceuticals, Inc. Tissue protective peptides and uses thereof
US8716245B2 (en) * 2005-08-05 2014-05-06 Araim Pharmaceuticals, Inc. Tissue protective peptides and uses thereof
US9340598B2 (en) 2005-08-05 2016-05-17 Araim Pharmaceuticals, Inc. Tissue protective peptides and uses thereof
US11266744B2 (en) 2005-08-12 2022-03-08 Amgen Inc. Modified Fc molecules
US10188740B2 (en) 2005-08-12 2019-01-29 Amgen Inc. Modified Fc molecules
EP2425860A1 (fr) 2005-08-12 2012-03-07 Amgen Inc. Molécules Fc modifiées
US9012605B2 (en) 2006-01-23 2015-04-21 Amgen Inc. Crystalline polypeptides
US8541201B2 (en) 2006-06-19 2013-09-24 Amgen Inc. Thrombopoietic compounds
US7981425B2 (en) 2006-06-19 2011-07-19 Amgen Inc. Thrombopoietic compounds
EP2738257A1 (fr) 2007-05-22 2014-06-04 Amgen Inc. Compositions et procédés pour produire des protéines de fusion bioactives
US8420779B2 (en) 2007-05-22 2013-04-16 Amgen Inc. Compositions and methods for producing bioactive fusion proteins
US8853358B2 (en) 2008-01-22 2014-10-07 Araim Pharmaceuticals, Inc. Tissue protective peptides and peptide analogs for preventing and treating diseases and disorders associated with tissue damage
US9580465B2 (en) 2008-01-22 2017-02-28 Araim Pharmaceuticals, Inc. Tissue protective peptides and peptide analogs for preventing and treating diseases and disorders associated with tissue damage

Also Published As

Publication number Publication date
WO1995021919A3 (fr) 1995-12-07

Similar Documents

Publication Publication Date Title
WO1995021919A2 (fr) Proteine a activite de thrombopoietine (tpo)
EP0668352A1 (fr) Protéine à activité TPO
Kato et al. Purification and characterization of thrombopoietin
JP2996415B2 (ja) 巨核球の成長と分化を刺激するモノｐｅｇ化ｍｇｄｆポリペプチド
RO117110B1 (ro) POLIPEPTIDA LIGAND mpl, ACID NUCLEIC, CARE O CODIFICA, VECTOR DE EXPRESIE, PROCEDEU PENTRU PRODUCEREA POLIPEPTIDEI LIGAND, SI COMPOZITIE FARMACEUTICA CU ACEASTA
BG63508B1 (bg) Хематопоетичен протеин и материали и методи за неговото получаване
WO1996023888A1 (fr) NOUVEAUX LIGANDS SE FIXANT A c-MPL
WO1995028907A2 (fr) La megapoietine: nouveau facteur favorisant la croissance des megakaryocytes
JPH11510062A (ja) 多機能性造血受容体アゴニスト
AU682581B2 (en) Compositions and methods using unbound MPL receptor for stimulating platelet production
AU702669B2 (en) Protein having TPO activity
JPH04506513A (ja) 巨核球増殖促進活性
JP2706704B2 (ja) 組換ヒト肝実質細胞増殖因子
RU2194074C2 (ru) Полипептид тромбопоэтин (тро), днк, кодирующая полипептид тро (варианты), способ получения полипептида (варианты), фармацевтическая композиция, способ лечения (варианты), антитело к полипептиду тро
AU722759B2 (en) Novel C-MPL receptor agonists
JP3635142B2 (ja) 抗ｔｐｏ抗体の作製方法
JP2991630B2 (ja) ヒトｔｐｏ活性を有するタンパク質をコードするｄｎａ
NO323195B1 (no) Protein som har TPO aktivitet, DNA kodende for nevnte protein, fremstillingsmetoder, vertceller, farmasoytiske sammensetinger, anvendelser og antistoff
JP2991640B2 (ja) ヒトｔｐｏ活性を有するタンパク質
US20040138430A1 (en) Novel polypeptide compose substance for promoting blood and blood vessel cell growth
JP3292873B2 (ja) 組換肝実質細胞増殖因子
JP3318323B2 (ja) 組換肝実質細胞増殖因子
JP4086904B2 (ja) 造血幹細胞増殖因子（ｓｃｇｆ）
JP2816971B2 (ja) 組換肝実質細胞増殖因子
MXPA98006628A (en) Gene of response of differentiation terminal honey honey noved

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 95190305.5

Country of ref document: CN

AK Designated states

Kind code of ref document: A2

Designated state(s): AM AT AU BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU JP KE KG KR KZ LK LR LT LU LV MD MG MN MW MX NL NO NZ PL PT RO RU SD SE SI SK TJ TT UA US US US US US US UZ VN

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): KE MW SD SZ UG AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 279555

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 2160591

Country of ref document: CA

Ref document number: 954889

Country of ref document: FI

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 1995908381

Country of ref document: EP

ENP Entry into the national phase in:

Ref document number: 1996 535025

Country of ref document: US

Date of ref document: 19960102

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 1995908381

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWE Wipo information: entry into national phase

Ref document number: 1019970702401

Country of ref document: KR

Ref document number: 1019970702400

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 1019970702400

Country of ref document: KR

Ref document number: 1019970702401

Country of ref document: KR

WWG Wipo information: grant in national office

Ref document number: 1019970702401

Country of ref document: KR

WWG Wipo information: grant in national office

Ref document number: 1019970702400

Country of ref document: KR

WWW Wipo information: withdrawn in national office

Ref document number: 1995908381

Country of ref document: EP